ArticleFrontiers in oncology2024
Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy-case report.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A review of the current evidence for maintenance therapy in gastric cancer.Frontiers in pharmacology · 2026Review
- Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Gastric cancer is the third leading cause of cancer-related mortality and the fifth most common cancer globally. In China, many patients are diagnosed at an advanced stage and cannot be operated on, so the prognosis is very poor. The role of maintenance therapy after first-line chemotherapy in gastric cancer is still unclear. Apatinib is a small-molecule VEGFR-2 TKI and is currently approved for third-line treatment after failure of second-line chemotherapy for advanced gastric cancer. In this article, we use case reports to illustrate its effectiveness and to study what effective maintenance treatments are available for gastric cancer. Methods: The main treatment is chemotherapy and targeted therapy. We reported a 68-year-old man with a diagnosis of advanced gastric cancer with liver metastasis. From 12/2014 to 05/2015 Oxaliplatin + S-1(dose) chemotherapy for 6 cycles, the efficacy of partial response (PR) evaluation. After the patient's oral S-1 + Apatinib (dose) to maintain the therapeutic usage and dosage, the patient is well tolerated, the tumor is reviewed regularly, and the condition is stable. The patient was finally infected with the COVID-2019 in May 2023, resulting in death after ineffective treatment. Results: After Oxaliplatin combined with S-1 regimen, the effect was up to PR. S-1 combined with Apatinib maintenance therapy after first-line chemotherapy, the patient has survived for more than 7 years without progression. Conclusions: The current treatment of advanced gastric cancer is not satisfactory. The combined application of S-1 and Apatinib in gastric cancer maintenance therapy deserves further study. Maintenance therapy for gastric cancer has attracted wide attention, and more large-scale clinical research is under way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.